BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38415699)

  • 1. Factors associated with longer survival among older medicare patients after diagnosis of supratentorial primary brain malignancies: a retrospective cohort study.
    Nguyen AV; Soto JM; Digbeu BD; Nguyen CY; Wu E; Huang JH; Kuo YF
    Neurol Res; 2024 May; 46(5):379-390. PubMed ID: 38415699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
    Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
    J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
    Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
    Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.
    Li PC; Huang RY; Yang YC; Hsieh KP; Yang YH
    BMC Cancer; 2022 Apr; 22(1):430. PubMed ID: 35443635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
    BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
    Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
    Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
    Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
    Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
    Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
    BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
    Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
    Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
    Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
    Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
    Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
    ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
    Htoo PT; Stürmer T; Jonsson-Funk M; Pate V; Simpson RJ; Lund JL
    Epidemiology; 2019 Nov; 30(6):867-875. PubMed ID: 31348009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.
    Sørensen GV; Ganz PA; Cole SW; Pedersen LA; Sørensen HT; Cronin-Fenton DP; Garne JP; Christiansen PM; Lash TL; Ahern TP
    J Clin Oncol; 2013 Jun; 31(18):2265-72. PubMed ID: 23650417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
    An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
    J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
    Liu X; Liu Y; Chen K; Yan S; Bai X; Li J; Liu D
    J Med Virol; 2021 Feb; 93(2):854-862. PubMed ID: 32687223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
    González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
    Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.